Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 - Episode 1

Overview of Molecular Testing and Barriers in mCRC

, , , ,

The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Overview of Molecular Testing and Barriers in mCRC
    EP. 2: Clinical Considerations for 2L Treatment Sequencing in mCRC
    EP. 3: Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
    EP. 4: Exploring Toxicities for Second Line Treatments in mCRC
    EP. 5: Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
    EP. 6: Factors Driving 3L Therapeutic Selection for mCRC
    EP. 7: Exploring Data Outcomes From the SUNLIGHT Trial
    EP. 8: Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
    EP. 9: Examining the Evolving 3L Treatment Landscape for mCRC
    EP. 10: Additional Key Takeaways of ASCO 2024 Data in mCR
    EP. 11: Future Outlooks in the Treatment of Metastatic Colorectal Cancer
    1. Dr Marshall to Dr Cohen: How would you describe the role of molecular testing for patients with mCRC?
      1. Which biomarkers are recommended for testing and when are patients tested?
    2. Dr Marshall to Panel: Briefly describe commonly used testing strategies of molecular markers for patients with mCRC.
      1. Is there a continued role for ctDNA in molecular testing for patients with mCRC?
      2. Dr Benson: What are some barriers to molecular testing in practice?

    x